{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:43:30Z","timestamp":1777131810561,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017964","name":"Tianjin Municipal Health Commission","doi-asserted-by":"publisher","award":["TJWJ2025QN114"],"award-info":[{"award-number":["TJWJ2025QN114"]}],"id":[{"id":"10.13039\/100017964","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.intimp.2026.116595","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:49:54Z","timestamp":1775656194000},"page":"116595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synergistic induction of ferroptosis by paclitaxel and sunitinib is mediated through SLC7A11 in lung cancer"],"prefix":"10.1016","volume":"179","author":[{"given":"Mengli","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huancheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunwa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116595_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168885","article-title":"Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy","volume":"22","author":"Kryczka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116595_bb0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.116595_bb0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12943-022-01579-9","article-title":"An EHMT2\/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116595_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114392","article-title":"Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies","volume":"160","author":"Hashemi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116595_bb0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116595_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.intimp.2026.116595_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/0008-5472.CAN-21-3432","article-title":"Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma","volume":"83","author":"Pan","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116595_bb0040","article-title":"RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway","volume":"8","author":"Xiong","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.intimp.2026.116595_bb0045","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/bph.16252","article-title":"Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics","volume":"180","author":"Wang","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116595_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.655316","article-title":"Angiogenesis inhibitors in small cell lung cancer","volume":"11","author":"Montanino","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116595_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2012.09.019","article-title":"A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer","volume":"79","author":"Han","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2026.116595_bb0060","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JTO.0b013e31821529c3","article-title":"Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer","volume":"6","author":"Schneider","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.116595_bb0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.lungcan.2012.03.009","article-title":"Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer","volume":"77","author":"Spigel","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2026.116595_bb0070","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","article-title":"Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (alliance)","volume":"33","author":"Ready","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116595_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2015.10.016","article-title":"Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)","volume":"54","author":"Abdelraouf","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116595_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbae016","article-title":"Cancer cell response to extrinsic and intrinsic mechanical cue: opportunities for tumor apoptosis strategies","volume":"11","author":"Shu","year":"2024","journal-title":"Regener. Biomater."},{"key":"10.1016\/j.intimp.2026.116595_bb0085","article-title":"Deubiquitylase USP52 promotes bladder cancer progression by modulating ferroptosis through stabilizing SLC7A11\/xCT","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.intimp.2026.116595_bb0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","article-title":"The cell biology of ferroptosis","volume":"25","author":"Dixon","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2026.116595_bb0095","article-title":"SLC7A11: the achilles heel of tumor?","volume":"15","author":"Jiang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116595_bb0100","article-title":"Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: a therapeutic strategy for triple-negative breast cancer","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.116595_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111760","article-title":"Apatinib combined with paclitaxel suppresses synergistically TNBC progression through enhancing ferroptosis susceptibility regulated SLC7A11\/GPX4\/ACSL4 axis","volume":"131","author":"Ma","year":"2025","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2026.116595_bb0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","article-title":"Drug resistance in cancer: molecular mechanisms and emerging treatment strategies","volume":"6","author":"Li","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.intimp.2026.116595_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105110","article-title":"Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib","volume":"161","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116595_bb0120","article-title":"Paclitaxel attenuates atherosclerosis by suppressing macrophage ferroptosis and improving lipid metabolism via the Sirt1\/Nrf2\/GPX4 pathway","volume":"39","author":"Liu","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2026.116595_bb0125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/CMAR.S497238","article-title":"Inhibitory effects of paclitaxel-loaded iron oxide nanoparticles on non-small cell lung cancer by enhancing autophagy-dependent ferroptosis and apoptosis pathways","volume":"17","author":"Deng","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.intimp.2026.116595_bb0130","first-page":"20143","article-title":"Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced cancer ferroptosis through the accumulation of ROS","volume":"16","author":"Wen","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.intimp.2026.116595_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111421","article-title":"TRIB3 knockdown increases the sensitivity of clear cell renal cell carcinoma to sunitinib by inducing ferroptosis","volume":"124","author":"Chen","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2026.116595_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217942","article-title":"OTUD3-mediated stabilization of SLC7A11 drives sunitinib resistance by suppressing ferroptosis in clear cell renal cell carcinoma","volume":"632","author":"Xu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116595_bb0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00280-009-1209-0","article-title":"Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase i dose-escalation study","volume":"66","author":"Robert","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116595_bb0150","article-title":"Pemetrexed sensitizes cisplatin therapy by inducing ferroptosis in NSCLC cells","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116595_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100916","article-title":"Overcoming cancer chemotherapy resistance by the induction of ferroptosis","volume":"66","author":"Wang","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.intimp.2026.116595_bb0160","article-title":"Inducing ferroptosis by traditional medicines: a novel approach to reverse chemoresistance in lung cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116595_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jcsm.13391","article-title":"Obesity worsens mitochondrial quality control and does not protect against skeletal muscle wasting in murine cancer cachexia","volume":"15","author":"Cardaci","year":"2024","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.intimp.2026.116595_bb0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1249\/MSS.0000000000002772","article-title":"Early-onset physical inactivity and metabolic dysfunction in tumor-bearing mice is associated with accelerated cachexia","volume":"54","author":"Counts","year":"2022","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.intimp.2026.116595_bb0175","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116595_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102703","article-title":"The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1","volume":"62","author":"Cheff","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2026.116595_bb0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.theriogenology.2017.11.031","article-title":"Inhibition of apoptosis by caspase inhibitor Z-VAD-FMK improves cryotolerance of in vitro derived bovine embryos","volume":"108","author":"Pero","year":"2018","journal-title":"Theriogenology"},{"key":"10.1016\/j.intimp.2026.116595_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/cvr\/cvt078","article-title":"Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function","volume":"99","author":"Feyen","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.intimp.2026.116595_bb0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-024-01772-w","article-title":"Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116595_bb0200","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202402139R","article-title":"The histone lactylation of AIM2 influences the suppression of ferroptosis by ACSL4 through STAT5B and promotes the progression of lung cancer","volume":"39","author":"Wu","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2026.116595_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-025-01624-2","article-title":"Epigenetic regulation of ACSL4 via H2A monoubiquitylation connects lipid metabolism to BAP1-mediated ferroptosis","author":"Fan","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2026.116595_bb0210","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41418-025-01452-4","article-title":"Redox regulation of TRIM28 facilitates neuronal ferroptosis by promoting SUMOylation and inhibiting OPTN-selective autophagic degradation of ACSL4","volume":"32","author":"Liu","year":"2025","journal-title":"Cell Death Differ."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926004406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926004406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:07:27Z","timestamp":1777129647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926004406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"alternative-id":["S1567576926004406"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116595","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic induction of ferroptosis by paclitaxel and sunitinib is mediated through SLC7A11 in lung cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116595"}}